SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Rheumatology and Clinical Immunology

[Return To Index page]
photo Larry W. Moreland, MD

Margaret Jane Miller Endowed Professor of Arthritis Research

Chief, Division of Rheumatology and Clinical Immunology

Email: morelandl@dom.pitt.edu

Phone: 412-383-8734

Contact
Office: 3500 Terrace Street
Pittsburgh, PA 15261
 
Phone: 412-383-8734
Fax: 412-648-8894
E-mail: morelandl@dom.pitt.edu
Administrative Assistant:
Matt Ceraso
Address: 3500 Terrace Street
BST S710
Pittsburgh, PA 15261
Email: mrc118@pitt.edu
Phone: 412-383-8734
Fax: 412-383-8864
Education and Training
Education
BS, West Liberty State College, 1979
MD, West Virginia University, 1983
Training
Internship (Internal Medicine), West Virginia University Medical Center, 1984
Residency (Internal Medicine), West Virginia University Medical Center, 1986
Chief Medical Residency, West Virginia University Medical Center, 1987
Fellowship,Rheumatology & Clinical Immunology, University of Alabama at Birmingham, 1990
Research Interest
Dr. Moreland's research interest is in translational research for diseases such as rheumatoid arthritis, vasculitis, lupus and seronegative spondyloarthropathies. He has extensive experience in clinical trials and long-term registries for patients with autoimmune diseases. Specific areas of interest are pathogenesis, biomarkers, and outcomes research. He has extensive collaborations with colleagues at the University of Pittsburgh as well as numerous investigators at other academic institutions. He currently is Director of the University of Pittsburgh and UPMC Rheumatoid Arthritis Center and Vasculitis Center.
Clinical Interest
Dr. Moreland is Director of the University of Pittsburgh and UPMC Rheumatoid Arthritis Center and Vasculitis Center. He has a special clinical interest in rheumatoid arthritis, vasculitis, lupus, gout and seronegative spondyloarthropathies.
Educational Interest
Dr. Moreland mentors Rheumatology fellows, medicine residents and medical students.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Moreland LW, Baumgartner SW, Schiff M, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of active, refractory rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc-Enbrel). New England Journal of Medicine. 1997; 337: 141-147.
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrision L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis: A randomized controlled trial. Annals of Internal Medicine. 1999; 130: 478-486.
Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E, Genovese M, Wasko M, Moreland LW, Weaver A, Markenson J, Finck B. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine. 2000; 343: 1586-1593.
Y Okada, D Wu, ..., LW Moreland, ..., RM Plenge. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014; 506(7488): 376-381.
Kremer J, Westhovens R, Leon M, DiGiorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah I, Williams G, Becker J-C, Hagerty D, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New England Journal of Medicine. 2003; 349: 1907-1915.
Hughes LB, Morrison D, Kelley JM, Padilla MA, Vaughan LK, Westfall AO, Dwivedi H, Mikuls TR, Holers VM, Parrish L, Alarcon GS, Conn DL, Jonas B, Callahan LF, Smith EA, Gilkeson G, Howard G, Moreland LW, Patterson N, Riech D. The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African-Americans through European genetic admixture. Arthritis and Rhematology. 2008; 58: 349-358.
Mikuls TR, Hughes LB, Westfall AO, Holers M, Parrish L, ...., Moreland LW. Cigarette smoking, disease severity, and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases. 2008; 67: 1529-1534.
LW Moreland, JR O'Dell, HE Paulus, ..., SS Cofield. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis and Rheumatism. 2012; 64(9): 2824-2835.
Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, Sokolove J, Chang Y, Chang Y, Parks CG, Wright NC, Moreland LW. Determinants of Mortality among Postmenopausal Women with Rheumatoid Arthritis in the Women's Health Initiative. Arthritis and Rheumatology. 2014; 66(3): 497-507.
Sponsored Research/Activities
Title: Abatacept (CTLA4-lg) for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangitis (Wegener's) (ABROGATE)
Role: Principal Investigator
Funding Agency: Cleveland Clinic
Start Year: 2015
End Year: 2019
Title: Central Pain Mechanisms, Pain Intensity and Drug Response in Rheumatoid Arthritis
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: R01 AR064850
Start Year: 2015
End Year: 2017
Title: Live Cell Autoreactive B-cell Capture for Advanced Analytics in RA
Role: Principal Investigator
Funding Agency: University of Minnesota
Start Year: 2015
End Year: 2016
Title: Treatments Against RA and Effect on FDG PET CT: The Target Trial
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: U01 AR068043
Start Year: 2015
End Year: 2016
Title: Type I Interferon and the Mechanism of TNF Antagonist in RA
Role: Co-Investigator
Funding Agency: Rheumatology Research Foundation
Start Year: 2015
End Year: 2016
Title: UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
Role: Principal Investigator
Funding Agency: National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: UH2 AR067685
Start Year: 2014
End Year: 2017
Title: Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis
Role: Co-Investigator
Funding Agency: Vasculitis Foundation
Start Year: 2014
End Year: 2017
Title: Vasculitis Clinical Research Consortium
Role: Principal Investigator
Funding Agency: University of Pennsylvania/National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: U54 AR057139
Start Year: 2014
End Year: 2016
Title: Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel Therapy in Rheumatoid Arthritis
Role: Principal Investigator
Funding Agency: Questcor Pharmaceuticals, Inc.
Grant Number: DRUG
Start Year: 2013
End Year: 2017
Title: RITAZAREM: An International, Open Label, Randomized, Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis
Role: Principal Investigator
Funding Agency: University of Pennsylvania
Start Year: 2013
End Year: 2016
Title: RF, CCP, SSA and More? SSA and Other CTD Autoantibody's Prevalence in African-American Patients with Rheumatoid Arthritis (ASPIRE)
Role: Principal Investigator
Funding Agency: Pfizer Inc.
Start Year: 2013
End Year: 2015
Title: Vasculitis Clinical Research Consortium
Role: Principal Investigator
Funding Agency: University of Pennsylvania/National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: U54 AR057319
Start Year: 2013
End Year: 2014
Title: Novel Methods for the Conduct of Clinical Trials
Role: Principal Investigator
Funding Agency: University of Pennsylvania/National Heart, Lung, & Blood Institute
Grant Number: R01 HL115041
Start Year: 2012
End Year: 2015
Title: Adaption and Validation of PROMIS for use in Vasculitis
Role: Principal Investigator
Funding Agency: University of Pennsylvania/National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: R01 AR064153
Start Year: 2012
End Year: 2015
Title: Rheumatoid Arthritis Comparative Effectiveness Research (RACER) Longitudinal Extension Study
Role: Principal Investigator
Funding Agency: Genentech, Inc.
Start Year: 2010
End Year: 2016
Title: Concurrent Pilot Studies in Giant Cell Arthritis and Takayasu's Arthritis to Examine the Safety, Efficacy & Immunologic Effects of Abatacept (CTLA4Ig) in Large Vessel Vasculitis (AGATA)
Role: Principal Investigator
Funding Agency: Cleveland Clinic/National Institute of Health
Start Year: 2010
End Year: 2015
Title: Amyloldosis Research Anti-TNF Therapies
Role: Principal Investigator
Funding Agency: Pittsburgh Foundation
Start Year: 2008
End Year: 2014
Title: NIAMS Multidisciplinary Clinical Research Center
Role: Principal Investigator
Funding Agency: University of Alabama at Birmingham/National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: P60 AR048095
Start Year: 2008
End Year: 2013
Title: Long-Term Extension Study of Safety During Treatment with Tocilzumab (MRA) in Patients Completing Treatment in MRA Core Studies, Protocol #WA 18696
Role: Principal Investigator
Funding Agency: Hoffman - LaRoche, Inc.
Grant Number: DRUG
Start Year: 2006
End Year: 2013
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, A Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis and Previously Treated with Anti TNFa Agent(s)
Role: Principal Investigator
Funding Agency: Centocor Company
Grant Number: DRUG
Start Year: 2006
End Year: 2013
Notable Achievements
American Society of Clinical Investigation (ASCI), 2001-Present
The Max Cooper Award for Research Excellence, UAB, 2002
West Liberty State College Alumni Association Wall of Honor, 2007
Margaret Jane Miller Endowed Professor for Arthritis Research Chair, University of Pittsburgh, 2007-Present
Top Doctors, Pitsburgh Magazine, 2012-Present